Manish Aghi, MD, PhD, MAS

Principal Investigator, Brain Tumor Research Center
Member, Helen Diller Family Comprehensive Cancer Center
Associate Professor
Department of Neurosurgery
Research Description: 

Manish Aghi is a neurosurgeon and scientist at University of California, San Francisco (UCSF). He completed his MD-PhD degrees through the MSTP program at Harvard Medical School, followed by neurological surgery residency and postdoctoral training at Massachusetts General Hospital. He is currently faculty in the department of neurological surgery and graduate division of biomedical sciences, as well as a principal investigator in the Brain Tumor Research Center at UCSF. His clinical practice is focused on the surgical management of brain and skull base tumors, with special emphasis on intraoperative brain mapping for glioma surgery, pituitary tumor surgery, and minimally invasive endoscopic skull base surgery. Work in the Aghi laboratory has been funded by NIH and private foundations since 2008 and is focused on the role of tumor-microenvironment interactions in driving aggressive biology and therapeutic resistance in benign and malignant brain tumors like pituitary adenomas and gliomas. Active areas of research include the role of tumor-associated macrophages in glioblastoma growth, whole genome sequencing of pituitary adenomas, metabolic changes occurring after anti-angiogenic therapy in glioblastoma, and the role of a tyrosine kinase-integrin receptor complex in driving invasive resistance in glioblastoma. He serves as PI on multiple industry sponsored and investigator-initiated phase I-II clinical trials comparing immunotherapy versus anti-angiogenic theray of recurrent glioblastoma, as well as investigating convection-enhanced delivery of oncolytic viruses and nanoliposomal chemotherapy to recurrent glioblastoma.

Primary Thematic Area: 
Cancer Biology & Cell Signaling
Secondary Thematic Area: 
Vascular & Cardiac Biology
Research Summary: 
Defining the interaction between tumor cells and the microenvironment in glioblastoma, including during therapeutic resistance

Websites

Publications: 

Clinical characteristics and outcomes of null-cell versus silent gonadotroph adenomas in a series of 1166 pituitary adenomas from a single institution.

Neurosurgical focus

Haddad AF, Young JS, Oh T, Pereira MP, Joshi RS, Pereira KM, Osorio RC, Donohue KC, Peeran Z, Sudhir S, Jain S, Beniwal A, Chopra AS, Sandhu NS, Theodosopoulos PV, Kunwar S, El-Sayed IH, Gurrola J, Blevins LS, Aghi MK

A Safe Transitions Pathway for post-craniotomy neurological surgery patients: high-value care that bypasses the intensive care unit.

Journal of neurosurgery

Young JS, Chan AK, Viner JA, Sankaran S, Chan AY, Imershein S, Meary-Miller A, Theodosopoulos PV, Jacques L, Aghi MK, Chang EF, Hervey-Jumper SL, Ward T, Gibson L, Ward MM, Sanftner P, Wong S, Amara D, Magill ST, Osorio JA, Venkatesh B, Gonzales R, Lau C, Boscardin C, Wang M, Berry K, McCullagh L, Reid M, Reels K, Nedkov S, Berger MS, McDermott MW

The influence of race and socioeconomic status on therapeutic clinical trial screening and enrollment.

Journal of neuro-oncology

Morshed RA, Reihl SJ, Molinaro AM, Kakaizada S, Young JS, Schulte JD, Butowski N, Taylor J, Bush NA, Aghi MK, Berger MS, Chang S, Clarke J, Hervey-Jumper SL

Anti-angiogenic therapies in the management of glioblastoma.

Chinese clinical oncology

Schulte JD, Aghi MK, Taylor JW